Kirilys Therapeutics to Present Preclinical Profile for KRLS-017, a reversible inhibitor of CDK7 for Oncology

First presentation of full preclinical profile of KRLS-017, a potentially best in class reversible small molecule inhibitor of Cyclin Dependent Kinase 7 (CDK7)

San Francisco, CA, December 11, 2023 — Kirilys Therapeutics, Inc., a multi-asset biotechnology company founded by investment firm Catalys Pacific and supported by Lightspeed Venture Partners, plans to present a detailed preclinical profile for KRLS-017 at AACR 2024 in San Diego, CA.

KRLS-017 is a potent, selective, and reversible inhibitor of Cyclin Dependent Kinase 7 (CDK7) and is being developed for the treatment of patients with advanced solid tumor malignancies. CDK7 function in control of both cell cycle and gene transcription, and overexpression of CDK7 is a poor prognostic indicator in breast, ovarian, gastric, and other tumor types.

The preclinical presentation titled “Preclinical evaluation of KRLS-017, a potent, highly selective and reversible CDK7 inhibitor with broad antitumor effect in preclinical models, in preparation for a Phase 1 clinical trial in advanced solid tumor malignancies” will include pharmacology, toxicology, and efficacy across several dosing schedules using in vivo tumor models. A Phase 1 clinical program for KRLS-017 is planned as a monotherapy dose escalation study in refractory solid tumors followed by an indication-specific cohort expansion that will include breast, ovarian and potentially other transcriptionally active tumor types to evaluate anti-tumor activity.


About Kirilys Therapeutics, Inc.
Kirilys Therapeutics, Inc. is a private, preclinical-stage biopharmaceutical company committed to the development of multiple precision oncology assets. Kirilys’ initial asset is KRLS-017, a novel CDK7 inhibitor with the potential to improve the treatment of multiple cancers. Kirilys is headquartered in San Francisco, CA. For more information about Kirilys, please visit


About Catalys Pacific
Catalys Pacific is a life sciences venture capital firm focusing on early-stage investments. The firm’s mission is to provide healthcare solutions for patients worldwide through the creation of and investment in biotech companies. Catalys Pacific is led by a global team versed in working closely with its partners in academia, biotech, venture capital and the pharmaceutical industry worldwide with an emphasis in Japan. The firm maintains offices in Tokyo and Kanagawa (Shonan Health Innovation Park), Japan and in San Francisco, California. For more information about Catalys Pacific, please visit


About Lightspeed Venture Partners
Lightspeed Venture Partners is a multi-stage venture capital firm focused on accelerating disruptive innovations and trends in the Enterprise, Consumer, and Health sectors. Over the past two decades, the Lightspeed team has backed hundreds of entrepreneurs and helped build more than 400+ companies globally. Lightspeed and its affiliates currently manage $10.5B across the global Lightspeed platform, with investment professionals and advisors in Silicon Valley, Israel, India, China, Southeast Asia, and Europe. For more information, please visit